€ 11.44
Key Takeaways
Risk factor
Considerable default risk
Profitability factor
Favourable analyst view
About
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally. The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems....
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITDA,
Target Price
The average target price of IBAB.BR is 17 and suggests 47% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
